Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications in Clinical Luminal Gastroenterology 2005-11 (Students, House Officers, Fellows, or Specialist Trainees in bold)

Scientist working in lab

Clinical Trials in IBD

RDP58 is a novel and potentially effective oral therapy for ulcerative colitis (UC): results of parallel prospective, multicenter, blinded, placebo-controlled trials. Travis SPL, Yap LM, Hawkey CJ, RDP Investigators' Study Group, Lazarov M, Warren BF, Fong T, Tesi RJ Inflamm Bowel Dis 2005;11:713-9.

Outcome measurement in clinical trials for ulcerative colitis: toward standardization. Cooney R, Warren BF, Altman DG, Abreu MT, Travis SPL. Trials 2007;8:17-25.

Once daily oral mesalazine for maintaining remission in ulcerative colitis is cost-saving compared to twice daily mesalazine: an economic evaluation based on the PODIUM randomised controlled trial. Connolly M, Nielsen S, Currie CJ, Poole CD, Travis SPL. J Crohn’s & Colitis 2009;3:32-37.

An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis using a simulated Markov model. Connolly MP, Nielsen SK, Currie CJ, Marteau P, Probert CSJ, Travis SPL J Crohn’s & Colitis 2009;3:168-174.

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. D'Haens GR, Fedorak R, Lémann M, Feagan BG, Kamm MA, Cosnes J, Rutgeerts PJ, Marteau P, Travis S, Schölmerich J, Hanauer S, Sandborn WJ; the IOIBD Membership. Inflamm Bowel Dis 2009;15:1599-604.

A placebo-controlled trial of visilizumab in patients with intravenous steroid refractory ulcerative colitis. Sandborn WJ, Colombel JF, Frankel M, Hommes DW, Lowder J, Mayer L, Plevy S, Stokkers P, Travis SPL, Van Assche G, Baumgart DC, Targan SR. Gut 2010 59:1485-92.

Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. Walters MJ, Wang Y, Lai N, Baumgart T, Zhao BN, Dairaghi DJ, Bekker P, Ertl LS, Penfold ME, Jaen JC, Keshav S, Wendt E, Pennell A, Ungashe S, Wei Z, Wright JJ, Schall TJ. J Pharmacol Exp Ther 2010;335:61-9.

Does it all ADA up? Adalimumab for ulcerative colitis Gut 2011;60:741-2.

Predicting outcome in IBD

Long term outcome after admission for acute severe ulcerative colitis in Oxford: the 1990-91 cohort. Bojic D, Radojicic Z, Nedeljkovic-Protic M, Al-Ali M, Jewell DP, Travis SPL. Inflamm Bowel Dis 2009;15:823-8.

Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Cassinotti A, Actis GC, Duca P, Massari A, Colombo E, Gai E, Annese V, D'Albasio G, Manes G, Travis S, Porro GB, Ardizzone S. Am J Gastroenterol 2009;104:2760-7.

The pattern and outcome of acute severe colitis. Dinesen L, Walsh A, Cummings JRF, Protic NM, Heap G, George B, Mortensen NM, Travis SPL. J Colitis and Crohn’s 2010;4:431-437

Predicting the need for colectomy in severe UC: a critical appraisal of clinical parameters and currently available biomarkers. Travis SPL, Satsangi J, Lémann M. Gut 2011;60:3-9

Randomised controlled trial: Early assessment after 2 weeks of high dose 5-ASA for moderately active UC. Orchard TR, van der Geest SAP, Travis SPL Aliment Pharmacol Ther 2011;33:1028-35.

Surgery in IBD

Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Hyder SA, Travis SPL, Jewell DP, George BD. Dis Colon Rectum 2006; 49:1837-41

Delayed surgery for acute severe colitis is associated with increased risk of post-operative complications. Randall J, Singh B, Warren BF, Travis SPL, Mortensen NJ, George BD. Br J Surg 2010;97:404-9

Ulcerative colitis. Travis SPL, Mortensen NJMcC. In: Anorectal and Colonic Diseases: A practical guide to their management (3rd Edition). Givel J-C, Mortensen NJ, Roche B Eds. Springer 2010; pp513-532.

Anorectal and colonic Crohn’s disease. Travis SPL, Mortensen NJMcC. In: Anorectal and Colonic Diseases: A practical guide to their management (3rd Edition). Givel J-C, Mortensen NJ, Roche B Eds. Springer 2010; pp501-512.

In favour of early surgery in Crohn’s disease: a hypothesis to be tested. Latella G, Caprilli R, Travis SPL. J Crohn’s & Colitis 2011;5:1-4.

Evaluating disease activity in IBD

Comparison between prospective and retrospective evaluation of Crohn's disease activity index. Frenz MB, Dunckley P, Camporota L, Jewell DP, Travis SPL. Am J Gastroenterol 2005;100:1117-20.

Impact of interobserver disagreement on phenotype-genotype associations in Crohn’s disease. Anna Oefferlbauer-Ernst, Wolfgang Miehsler, Otto Eckmüllner, Thomas Waldhoer, Clemens Dejaco, Alfred Gangl, Harald Vogelsang, Simon Travis, Walter Reinisch. Inflammatory Bowel Diseases 2007; 13:156-63.

Which activity index for ulcerative colitis (UC)? Evaluation of inter-observer variation of symptomatic, endoscopic and composite scores. Walsh AJ, Brain AOS, Keshav S, Buchel OC, Jacobovits S,  Merrin B, Thomas S, Rolinski M, White L, Von Herbay A, Warren BF, Altman DG, Travis SPL. Gastroenterology 2009 (oral presentation)

How variable is the Mayo score between observers and might this affect clinical trial recruitment or outcome? Walsh AJ, Brain AOS, Keshav S, Buchel OC, Jacobovits S,  Merrin B, Thomas S, Rolinski M, White L, Von Herbay A, Warren BF, Altman DG, Travis SPL. Gastroenterology 2009 (poster of distinction).

How much agreement is there between histological, endoscopic and clinical assessments of remission in ulcerative colitis? Thomas S, Walsh A, Von Herbay A, Buchell OC, Brain AO, Keshav S, Warren BF, Travis SPL. Gut 2009;58 Suppl1: A117.

Development of the Lémann Crohn’s Disease Digestive Damage Score (CD3S). Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, Chowers Y, D'Haens G, Feagan BG, Hibi T, Hommes DW, Irvine EJ, Kamm MA, Loftus EV, Louis E, Michetti P, Munkholm P, Oresland T, Panés J, Peyrin-Biroulet L, Reinisch W, Rutgeerts P, Sands BE, Schölmerich J, Schreiber S, Tilg H, Travis SPL, Vecchi M, Wong CJ, Mary J-Y, Colombel J-F, Lémann M. Inflamm Bowel Dis 2010 (epub Nov 9)

Endoscopy

Role of small bowel endoscopy in the management of patients with IBD: an international OMED-ECCO Consensus. Arnaud Boureille*, Ana Ignjatovic*, Lars Aabakken, Edward V Loftus Jr, Rami Eliakim, Marco Pennazio, Yoram Bouhnik, Jochen Kammermeier, Martin Keuchel, JG Albert, Paul F Fortun, Graham Radford-Smith, JG Albert, Sandro Ardizonne, Simon Bar-Meir, Raf Bisschops, Edward J Despott, Paul F Fortun, Rob Heuschkel, Jonathan A Leighton, Gerassimos J. Mantzaris, Driffa Moussata, Simon Lo, Vemund Paulsen, Julián Panés, Graham Radford-Smith, Walter Reinisch, E Rondonotti, David S Sanders, Ernest Seidman, Jason M Swoger, Hironori Yamamoto, Simon Travis, Jean-Frédéric Colombel, Andre Van Gossum, on behalf of the Organisation Mondial d’Endoscopie Digestif (OMED) and the European Crohn’s and Colitis Organisation (ECCO). Endoscopy 2009;41:618-37 (*contributed equally)

Addition of senna improves quality of colonoscopy preparation with magnesium citrate. Vradelis S, Kalaitzakis E, Sharifi Y, Buchel O, Keshav S, Chapman RW, Braden B. World J Gastroenterol 2009;15:1759-63.

Quality control in upper gastrointestinal endoscopy: detection rates of gastric cancer in Oxford 2005-2008. Vradelis S, Maynard N, Warren BF, Travis SPL. Postgrad Med J 2011;87:335-9.
 
Development of an ulcerative colitis endoscopic index of severity (UCEIS). Travis SPL, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lémann M, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Bernhardt CA, Mary JY, Sandborn WJ. Gut 2011 [epub Oct 13]

Burden of disease in IBD

Perianal diseases explained. Jakobovits S, Travis SPL. CORE information booklet 2006.

Is IBD associated with a stressful lifestyle? Dunckley P, Travis SPL. Inflamm Bowel Dis 2008;14 Suppl 2:S33-4.

Inflammatory bowel disease in 2009. Bailey A, Travis SPL. In: Horizons in Medicine. Ed Friedland J. Royal College of Physicians of London 2009; pp81-91.

Incidence and clinical significance of immunogenicity to infliximab in Crohn’s disease: a critical systematic review. Cassinnotti A, Travis SPL. Inflamm Bowel Dis 2009;15:1264-75.

IBD and IBS: Novel mechanisms and future practice. Travis SPL, Spiller R, Holzer P, Colombel JF. Digestive Diseases 2009;29 suppl 1:1-3.

IBD care in Europe: a comparative audit of the inpatient management of Crohn’s disease and ulcerative colitis using the National UK IBD audit tool. Cassinotti A, Keshav S, Aridizzone S, Mortensen N, Sampietro G, Fociani P, Duca P, George B, Lazzaroni M, Manes G, Warren BF, Foschi D, Vago G, Bianchi Porro G, Travis SPL. J Crohns Colitis 2009;3:291-301.

The role of immunization in reducing infections in patients with inflammatory bowel disease. JF Rahier, JF Colombel, SPL Travis. IBD Monitor 2009;9:106-10.

Review article: Influenza A (H1N1) virus in patients with inflammatory bowel disease. Rahier JF, Viget N, Yazdanpannah Y, Travis SPL, Colombel JF. Aliment Pharmacol Ther 2010;31:5-10.

How to manage the infectious risk under anti-TNF in inflammatory bowel disease. Culver EL, Travis SPL. Curr Drug Targets 2010:11:198-218.

What is the optimal treatment for anemia in inflammatory bowel disease? Kent A, Blackwell VJ, Travis SPL. Curr Drug Delivery 2011 [epub Oct 21]

Development of the Lémann Crohn’s Disease Digestive Damage Score (CD3S). Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, Chowers Y, D'Haens G, Feagan BG, Hibi T, Hommes DW, Irvine EJ, Kamm MA, Loftus EV, Louis E, Michetti P, Munkholm P, Oresland T, Panés J, Peyrin-Biroulet L, Reinisch W, Rutgeerts P, Sands BE, Schölmerich J, Schreiber S, Tilg H, Travis SPL, Vecchi M, Wong CJ, Mary J-Y, Colombel J-F, Lémann M. Inflamm Bowel Dis 2011;17:1415-22.

Mortality in patients hospitalized with Crohn’s disease. Siffledeen J, Goldacre MJ, Travis SPL Aliment Pharmacol Ther 2011 (invited commentary in press)

Clinical management of IBD

The management of acute severe ulcerative colitis. Jakobovits S, Travis SPL. British Medical Bulletin 2006; 75-76:131-44.

Targeting nanomedicines in the treatment of Crohn’s Disease: focus on Certolizumab pegol (CDP870). Dinesen L, Travis SPL. International Journal of Nanomedicine 2007; 2:39-47.

Toxic dilatation in ulcerative colitis. Evans K, Travis SPL. Medicine 2007 (invited review) available on line 2006; http://dx.doi.org/10.1016/j.mpmed.2006.12.006

Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease. Steinhart AH, Forbes A, Rodgers-Gray BS, Mills EC, Travis SPL Aliment Pharmacol Ther 2007; 25:1389-99.

Management of Crohn’s disease today – the European perspective. Walsh A, Easdale M, Travis SPL. Practical Gastroenterology 2007;31:54-65.

What do patients with inflammatory bowel disease want for their clinical management? Westwood N, Travis SPL. Aliment Pharmacol Ther 2008; 27 Suppl 1: 1-8

How do you avoid and treat steroid side-effects? Travis SPL. Inflamm Bowel Dis 2008;14 Suppl 2:S14-5.

The management of Crohn’s disease. Cummings JFR, Keshav S, Travis SPL (invited review) Br Med J 2008;336:1062-6

Standard therapy for the management of ulcerative colitis and Crohn’s disease: the ECCO Guidelines. Ignjatovic A, Travis SPL. In: Ferkolj I, Galle PR, Gangl A, Vucelic B, Eds. Pathogenesis and clinical practice in Gastroenterology Falk Symposium 160 2008; pp 76-89.

Therapy for ulcerative colitis: State of the art. Brain AO, Travis SPL. Current Opinion in Gastroenterology 2008;24:469-474.

Systematic Review: Does concurrent therapy with 5-ASA and immunomodulator(s) in inflammatory bowel disease improve outcomes? Andrews JM, Travis SPL, Gibson PR, Gasche C. Aliment Pharmacol Ther 2009;29:459-69.

Therapeutic approaches to managing Crohn’s disease. Travis SPL. In: Inflammatory bowel disease: translating basic science into clinical practice. Targan S, Shanahan F, Karp L Eds. Wiley-Blackwell 2010; pp469-80.

Biologicals and malignancy: now or never? Lust M, Travis SPL. Clinical Dilemmas in IBD. Irving P, Rampton DS, Seigel C, Shanahan F Eds. Blackwell Publishing 2011 (in press)

Colon salvage therapy for acute severe colitis: cyclosporine or infliximab? Burger DC, Travis SPL. Curr Opin Gastroenterol 2011;27:358-62.

Conventional treatment of inflammatory bowel disease. Burger DC, Travis SPL Gastroenterology 2011;140:1827-37 (invited review)

Physician perspectives on unresolved issues in the use of conventional therapy in Crohn’s disease: results from an international survey and discussion programme. Ferrante M, Karmiris K, Newnham E, Siffledeen, Zelinkova Z, van Assche G, Lakatos PL, Panés J, Sturm A, Travis SPL, van der Woude CJ, Reinisch R, Colombel J-F, Panaccione R. J Crohns Colitis 2011 (in press)

International guidelines on the management of IBD

European Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. EF Stange*, SPL Travis*, S Vermeire, K Geboes, W Reinisch, A Barakauskiene, R Feakins, JF Fléjou, H Herfarth, DW Hommes, L Kupcinskas, PL Lakatos, GJ Mantzaris, S Schreiber, V Villanacci, BF Warren for the European Crohn's and Colitis Organisation (ECCO). J Crohn’s & Colitis 2008;2:1-23.

European Consensus on the diagnosis and management of ulcerative colitis: current management. Travis SPL*, Stange EF*, Lémann M, Øresland T, Bemelman WA, Chowers Y, Colombel JF, D'Haens G, Ghosh S, Marteau P, Kruis W, Mortensen NJMcC, Penninckx F, Gassull M, for the European Crohn's and Colitis Organisation (ECCO). J Crohn’s & Colitis 2008;2:24-62.

European Consensus on the diagnosis and management of ulcerative colitis: Special situations. Livia Biancone, Pierre Michetti, Simon Travis, Johanna C. Escher, Gabriele Moser, Alastair Forbes, Jörg C Hoffmann, Axel Dignass, Paolo Gionchetti, Günter Jantschek, Ralf Kiesslich, Sanja Kolacek, Rod Mitchell, Julian Panes, Johan Soderholm, Boris Vucelic, Eduard Stange for the European Crohn's and Colitis Organisation (ECCO). J Crohn’s & Colitis 2008;2:63-92.

European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. Rahier J-F, S Ben-Horin, Cowers Y, Conlon C, De Munter P, D’Haens G, Domenech E, Eliakim R, Eser A, Frater J, Gassull M, Giladi M, Kaser A, Lémann  M, Moreels T, Moschen A,  Pollok R, Reinisch W, Schunter M, Stange EF, Tilg H, Van Assche G, Viget N, Vucelic B, Walsh A, Weiss G, Yazdanpanah Y, Zabana Y, Travis SPL and JF Colombel on behalf of the European Crohn’s and Colitis Organisation (ECCO).  J Crohn’s and Colitis 2009;3:47-91.

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. Van Assche G*, Dignass A*, Panes J, Reinisch W, Beaugerie L, Karagiannis J, Allez M, Ochsenkühn T, Orchard T, Rogler G, Louis E, Mantzaris G,  Warren BF, Geboes K, Travis SPL, Stange EF, for the European Crohn's and Colitis Organisation (ECCO). J Crohn’s & Colitis 2010;4:7-27. (* contributed equally)

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. Dignass A*, Van Assche G*. Lindsay JO, Lémann M, Söderholm J, Colombel JF, Danese S, D'Hoore A, Gassull M, Gomollón F, Hommes DW, Michetti P, O’Morain C, Öresland T, Windsor A, Stange EF and Travis SPL, for the European Crohn's and Colitis Organisation (ECCO). J Crohn’s & Colitis 2010;4:28-62 (*contributed equally)

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. Van Assche G*, Dignass A*; Reinisch W, van der Woude CJ, Sturm A, De Vos M, Guslandi M, Oldenburg B, Dotan I, Marteau P, D’Haens G, Gionchetti P, Vucelic B Söderholm J, Escher J, Koletzko S, Kolho K-J, Lukas M,  Mottet C, Tilg H, Vermeire S,  Carbonnel F, Cole A, Novacek G, Reinshagen M, Tsianos E, Herrlinger K, Bouhnik Y, Kiesslich R, Stange EF, Travis SPL, Lindsay J for the European Crohn's and Colitis Organisation. J Crohn’s & Colitis 2010;4:63-101. (*contributed equally)

The London Position Statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn’s and Colitis Organisation: when to start, when to stop which drug to choose and how to predict response? D’Haens G*, Panaccione R*, Higgins PDR, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm MA, Lofberg R, Quary A, Sands BE, Sood A, Watermeyer G, Lashner  B, Lémann M, Plevy  S, Reinisch W, Schreiber S, Siegel C, Targan  S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF and Travis SPL. Am J Gastroenterol 2011;106:199-212.

The London Position Statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn’s and Colitis Organisation: pregnancy and paediatrics. Mahadevan U, Cucchiara S, Hyams J, Steinwurtz F, Nuti F, Travis SPL, Sandborn WJ, Colombel JF. Am J Gastroenterol 2011;106:214-23.

The London Position Statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn’s and Colitis Organisation: Safety. Van Assche G, Lewis JD, Lichtenstein G, Loftus EV, Ouyang  Q, Panes J, Sandborn WJ, Travis SPL, Colombel  JF.  Am J Gastroenterol 2011;106:1594-602.

Defining remission in ulcerative colitis. Travis SPL, Higgins PDR, Orchard T, Van der Woude CJ, Panacionne R, Bitton A, O’Morain C, Panes J, Sturm A, Reinisch W, Kamm MA, D’Haens G. Aliment Pharmacol Ther 2011;34:113-124. (in top 10 downloaded papers 2011)

Blood transfusion in acute upper GI bleeding

The role of blood transfusion in the management of upper and lower intestinal tract bleeding. Hearnshaw S, Travis SPL, Murphy M. Best Practice and Research Clinical Gastroenterology 2008;22:355-71

Red cell transfusion for the management of upper gastrointestinal haemorrhage. Hearnshaw S, Brunskill S, Doree C, Hyde C, Travis S, Murphy MF. Cochrane Database Systematic Review 2009;2:CD006613.

Use of endoscopy for management of acute upper gastrointestinal bleeding in the UK: results of a nationwide audit. SA Hearnshaw, RFA Logan, D Lowe, MF Murphy, SPL Travis, KR Palmer. Gut 2010;59:1022-29.

Outcomes following early red blood cell transfusion in acute upper gastrointestinal haemorrhage. SA Hearnshaw, RFA Logan, KR Palmer, T Card, SPL Travis, MF Murphy. Aliment Pharmacol Ther 2010;32:215-24.

Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK Audit. SA Hearnshaw, RFA Logan, D Lowe, MF Murphy, SPL Travis, KR Palmer. Gut 2011;60:1327-35.

Mortality from acute upper gastrointestinal bleeding in the UK- Does it display a “Weekend Effect”? Jairath V, Kahan BA, Hearnshaw SA, Logan RFA, Travis SPL, Murphy MF, Palmer KR. Am J Gastroenterol 2011;106:1621-8.

Red cell transfusion practice in patients presenting with acute upper gastrointestinal bleeding - A survey of 815 UK clinicians. Jairath V, Logan RF, Travis SPL, Palmer K, Murphy M. Transfusion 2011;51:1940-8.

Surgery or radiological embolisation after failed endoscopic haemostasis for non-variceal upper gastrointestinal bleeding? Results from a nationwide study. Jairath V, Kahan BC, Logan RFA, Dore CJ, Hearnshaw SA, Travis SPL, Murphy MF, Palmer KR. GI Endoscopy 2011 (in press)

Outcomes following acute nonvariceal upper gastrointestinal bleeding in relation to time to endoscopy: results from a nationwide study. Jairath V, Kahan BC, Logan RFA, Doree C, Hearnshaw S, Travis SPL, Murphy MF, Palmer KR. (submitted to Endoscopy 2011)

Microscopic gut inflammation

Collagenous gastritis. Brain AO, Rajunan C, Mee AS, Warren BF, Travis SPL. Eur J Gastrenterol Hepatol 2009;21:1419-24.

IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. Alessandra Geremia A, Arancibia-Cárcamo CV, Fleming MPP, Rust N, Singh B, Travis SPL, Powrie F. J Exp Med 2011;208:1127-33.

Coeliac disease

A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Van Heel D, Franke L, Hunt KA, Gwilliam R, Zhernakove A, Inouye M, Wapenaar MC, Barnardo MCNM, Bethel G, Holmes GKT, Feighery C, Jewell DP, Kelleher D, Kumar P, Travis SPL, Walters JRF, Sanders DS, Howdle P, Swift J, Playford RJ, McLaren WA, Mearin ML, Mulder CJ, McManus R, McGinnis R, Cardon LR, Deloukas P, Wijmenga C. Nature Genetics 2007;39:827-9.

Insights from clinical practice

Inflammatory bowel disease, peptic ulcer and diverticular disease as certified causes of death in an English population 1979-2003. Goldacre MJ, Duncan M, Cook-Mozaffri P, Griffith M, Travis SPL. Eur J Gastroenterol Hepatol 2008; 20:96-103.

Posterior scleritis and orbital myositis as extra-intestinal manifestations of Crohn’s disease: a systematic review. EL Culver, J Salmon, P Frith, SPL Travis. J Crohn's & Colitis 2008;2:337-342.

Obstructing giant post-inflammatory polyposis in ulcerative colitis: case report and review of the literature. JRL Maggs, L Browning, BF Warren, SPL Travis. J Crohn’s & Colitis 2008;2:170-180.

The role of CMV in steroid-resistant ulcerative colitis: a systematic review. Ayre K, Warren BF, Jeffrey K, Travis SPL J Crohn’s & Colitis 2009;3:141-8.

Clinical challenges and images in GI. Intestinal posttransplant lymphoproliferative disorder. Brain O, von Herbay A, Keshav S. Gastroenterology 2009;136:1506, 1845.

Intraductal papillary mucinous neoplasm in chronic calcifying pancreatitis: egg or hen? Kalaitzakis E, Braden B, Trivedi P, Sharifi Y, Chapman R. World J Gastroenterol 2009;15:1273-5.

Is anti-TNF therapy always prohibited in patients with inflammatory bowel disease and previous malignancy? Lust M, Travis SPL. Practical Gastroenterology 2009;33:25-30.

Immune-mediated and chronic inflammatory disease in people with sarcoidosis: disease associations in a large UK database. Rajoriya N, Wotton CJ, Yeates DGR, Travis SPL, Goldacre M. Postgrad Med J 2009;85:233-7

Toxic megacolon Blackwell VJ, Travis SPL. Medicine 2011;39:105-7.

Review of gastric cancer risk factors in patients with common variable immunodeficiency disorders: proposal for a surveillance programme. Dhalla F, Pereira da Silva S, Lucas M, Travis SPL, Chapel H. Clin Exp Immunol 2011;165:1-7. (in top 10 downloaded papers 2011)

A unique clinical phenotype of primary sclerosing cholangitis associated with Crohn’s disease. JS Halliday, J Djordjevic, E Culver, M Lust, B Braden, SPL Travis, RWG Chapman. J Crohns Colitis 2011 (in press)

Risk of colorectal neoplasia in patients with colonic Crohn´s disease and concomitant primary sclerosing cholangitis. Braden B, Halliday J, Aryasingha S, Sharifi S, Checchin D, Warren BF, Kitiyakara T, Travis SPL, Chapman RWG Clin Gastroenterol Hepatol 2011 [epub Oct 27]

An unusual case of dyspnoea in an elderly male. Trivedi PJ, Canavan J, Holloway C, Slater A, Travis SPL. Br Med J Case reports 2011 (in press)

Keeping abdominal pain in the family. Cahill TJ, Slater A, Travis SPL Gut 2011 (in press).

Exposure to hookworms in patients with Crohn’s disease. Shale M, Travis SPL. Aliment Pharmacol Ther 2011;34:1248-9

Miscellaneous

Weight loss at high altitude: Pathophysiology and practical implications. N Hamad, Travis SPL Eur J Gastroenterol Hepatol 2006; 18:5-10.

15 year audit of home parenteral nutrition provision at the John Radcliffe Hospital, Oxford. Green C, Mountford G, Hamilton H, Kettlewell MGW, Travis SPL Postgrad Med J 2008; 101:365-9.

Book: Case studies in Gastroenterology. Walsh A, Buchel OC, Collier J, Travis SPL. Oxford University Press (2010)

Gastrointestinal function, dysfunction and weight loss. Hamad N, Travis SPL. In: High altitude: Human adaptation to hypoxia. Ed Erik R Swenson, Peter Bartsch.  2012 (in press)